BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 11367061)

  • 1. Cost of medical care, once falling, may be starting to rise again.
    AIDS Policy Law; 1999 Oct; 14(20):5. PubMed ID: 11367061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of managed HIV care remains stable, study says.
    AIDS Policy Law; 1998 Oct; 13(19):15. PubMed ID: 11365949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
    Krentz HB; Auld MC; Gill MJ;
    CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
    Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
    Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of care for HIV infection in a managed care population from 1995 to 1997.
    Lapins DL; Urdaneta ME; Barrett J; Hamel EC; Duong PT; Markson LE
    Am J Manag Care; 2000 Sep; 6(9):973-81. PubMed ID: 11184068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs associated with combination antiretroviral therapy in HIV-infected patients.
    Yazdanpanah Y
    J Antimicrob Chemother; 2004 Apr; 53(4):558-61. PubMed ID: 14985277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006.
    Krentz HB; Gill MJ
    HIV Med; 2008 Oct; 9(9):721-30. PubMed ID: 18643856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa.
    Rosen S; Long L; Sanne I
    Trop Med Int Health; 2008 Aug; 13(8):1005-15. PubMed ID: 18631314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
    Marseille E; Saba J; Muyingo S; Kahn JG
    AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychiatric disorders in HIV infection: impact of diagnosis on economic costs of care.
    Yeung H; Krentz HB; Gill MJ; Power C
    AIDS; 2006 Oct; 20(16):2005-9. PubMed ID: 17053346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustaining treatment costs: who will pay?
    Zewdie D; De Cock K; Piot P
    AIDS; 2007 Jul; 21 Suppl 4():S1-4. PubMed ID: 17620744
    [No Abstract]   [Full Text] [Related]  

  • 13. The economics of effective AIDS treatment in Thailand.
    Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
    AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.
    Pinkerton SD; Martin JN; Roland ME; Katz MH; Coates TJ; Kahn JO
    Arch Intern Med; 2004 Jan; 164(1):46-54. PubMed ID: 14718321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART.
    Stoll M; Claes C; Schulte E; Graf von der Schulenburg JM; Schmidt RE
    Eur J Med Res; 2002 Nov; 7(11):463-71. PubMed ID: 12568973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Economic burden and clinical course of HIV infection and AIDS today: how the variation of natural history, available treatments, and strictly related costs play a role in needs of health care].
    Manfredi R; Calza L; Gramegna A; Bocchi F; Fiacchi P; Corsini D; Chiodo F
    Recenti Prog Med; 2001 Nov; 92(11):648-54. PubMed ID: 11765655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
    Desai K; Sansom SL; Ackers ML; Stewart SR; Hall HI; Hu DJ; Sanders R; Scotton CR; Soorapanth S; Boily MC; Garnett GP; McElroy PD
    AIDS; 2008 Sep; 22(14):1829-39. PubMed ID: 18753932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic impact of HIV.
    Veenstra N; Whiteside A
    Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):197-210. PubMed ID: 15778110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.